Skip to content

Study · Not a test of the peptide alone · 2023

2 results

Development and Characterization of Innovative Multidrug Nanoformulation for Cardiac Therapy.

Gendron A, Domenichini S, Zanna S, Gobeaux F, Piesse C, Desmaële D, Varna M

Materials (Basel, Switzerland)22 Feb 2023Cited by 2 (Europe PMC)

PMID36902927 (opens in a new tab)PMCIDPMC10003764 (opens in a new tab)DOI10.3390/ma16051812 (opens in a new tab)PepBankPUB-36902927
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

For several decades, various peptides have been under investigation to prevent ischemia/reperfusion (I/R) injury, including cyclosporin A (CsA) and Elamipretide. Therapeutic peptides are currently gaining momentum as they have many advantages over small molecules, such as better selectivity and lower toxicity. However, their rapid degradation in the bloodstream is a major drawback that limits their clinical use, due to their low concentration at the site of action. To overcome these limitations, we have developed new bioconjugates of Elamipretide by covalent coupling with polyisoprenoid lipids, such as squalenic acid or solanesol, embedding self-assembling ability. The resulting bioconjugates were co-nanoprecipitated with CsA squalene bioconjugate to form Elamipretide decorated nanoparticles (NPs). The subsequent composite NPs were characterized with respect to mean diameter, zeta potential, and surface composition by Dynamic Light Scattering (DLS), Cryogenic Transmission Electron Microscopy (CryoTEM) and X-ray Photoelectron Spectrometry (XPS). Further, these multidrug NPs were found to have less than 20% cytotoxicity on two cardiac cell lines even at high concentrations, while maintaining an antioxidant capacity. These multidrug NPs could be considered for further investigations as an approach to target two important pathways involved in the development of cardiac I/R lesions.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Safety outcome

    Multidrug nanoparticles of elamipretide and cyclosporin A bioconjugates had less than 20% cytotoxicity on two cardiac cell lines, even at high concentrations.

    In plain wordsIn lab tests, nanoparticles of elamipretide and cyclosporin A conjugates killed fewer than 20% of cells in two heart cell lines.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableCytotoxicity in cardiac cell lines
    Study

    n: not reported in source

    two cardiac cell lines
    Outcome group
    Adverse events · Cardiovascular

    Measurements

    Cytotoxicity
    < 20%
    two cardiac cell lines

    Source sentences

    Summary
    these multidrug NPs were found to have less than 20% cytotoxicity on two cardiac cell lines even at high concentrations
    1 context sentence
    Summary · context
    The resulting bioconjugates were co-nanoprecipitated with CsA squalene bioconjugate to form Elamipretide decorated nanoparticles (NPs).

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Activity measurement

    Multidrug nanoparticles of elamipretide and cyclosporin A bioconjugates maintained antioxidant capacity.

    In plain wordsIn lab tests, nanoparticles of elamipretide and cyclosporin A conjugates kept their antioxidant capacity.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeAntioxidant capacity
    Study

    n: not reported in source

    two cardiac cell lines
    Outcome group
    Mitochondrial function · Cardiovascular

    Source sentences

    Summary
    while maintaining an antioxidant capacity.
    1 context sentence
    Summary · context
    The resulting bioconjugates were co-nanoprecipitated with CsA squalene bioconjugate to form Elamipretide decorated nanoparticles (NPs).

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.